Pranav Murthy1, Mazen S Zenati1,2, Amr I Al Abbas1, Caroline J Rieser1, Nathan Bahary3,4, Michael T Lotze1,5,6, Herbert J Zeh7, Amer H Zureikat1, Brian A Boone8. 1. Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA, USA. 5. Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. 6. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. 7. Department of Surgery, University of Texas Southwestern, Dallas, TX, USA. 8. Department of Surgery, West Virginia University, Morgantown, WV, USA. Brian.boone@hsc.wvu.edu.
Abstract
BACKGROUND: The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed at diagnosis. Neoadjuvant therapy (NAT) is increasingly used in the treatment of PDAC. However, biomarkers of response are lacking. This study aimed to determine the prognostic significance of SII before and after NAT and its association with the pancreatic tumor biomarker carbohydrate-antigen 19-9 (CA 19-9). METHODS: This study retrospectively analyzed all PDAC patients treated with NAT before pancreatic resection at a single institution between 2007 and 2017. Pre- and post-NAT lab values were collected to calculate SII. Absolute pre-NAT, post-NAT, and change in SII after NAT were evaluated for their association with clinical outcomes. RESULTS: The study analyzed 419 patients and found no significant correlation between pre-NAT SII and clinical outcomes. Elevated post-NAT SII was an independent, negative predictor of overall survival (OS) when assessed as a continuous variable (hazard ratio [HR], 1.0001; 95% confidence interval [CI] 1.00003-1.00014; p = 0.006). Patients with a post-NAT SII greater than 900 had a shorter median OS (31.9 vs 26.1 months; p = 0.050), and a post-NAT SII greater than 900 also was an independent negative predictor of OS (HR, 1.369; 95% CI 1.019-1.838; p = 0.037). An 80% reduction in SII independently predicted a CA 19-9 response after NAT (HR, 4.22; 95% CI 1.209-14.750; p = 0.024). CONCLUSION: Post-treatment SII may be a useful prognostic marker in PDAC patients receiving NAT.
BACKGROUND: The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed at diagnosis. Neoadjuvant therapy (NAT) is increasingly used in the treatment of PDAC. However, biomarkers of response are lacking. This study aimed to determine the prognostic significance of SII before and after NAT and its association with the pancreatic tumor biomarker carbohydrate-antigen 19-9 (CA 19-9). METHODS: This study retrospectively analyzed all PDACpatients treated with NAT before pancreatic resection at a single institution between 2007 and 2017. Pre- and post-NAT lab values were collected to calculate SII. Absolute pre-NAT, post-NAT, and change in SII after NAT were evaluated for their association with clinical outcomes. RESULTS: The study analyzed 419 patients and found no significant correlation between pre-NAT SII and clinical outcomes. Elevated post-NAT SII was an independent, negative predictor of overall survival (OS) when assessed as a continuous variable (hazard ratio [HR], 1.0001; 95% confidence interval [CI] 1.00003-1.00014; p = 0.006). Patients with a post-NAT SII greater than 900 had a shorter median OS (31.9 vs 26.1 months; p = 0.050), and a post-NAT SII greater than 900 also was an independent negative predictor of OS (HR, 1.369; 95% CI 1.019-1.838; p = 0.037). An 80% reduction in SII independently predicted a CA 19-9 response after NAT (HR, 4.22; 95% CI 1.209-14.750; p = 0.024). CONCLUSION: Post-treatment SII may be a useful prognostic marker in PDACpatients receiving NAT.
Authors: Ching-Wei D Tzeng; Aparna Balachandran; Mediha Ahmad; Jeffrey E Lee; Sunil Krishnan; Huamin Wang; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Peter W T Pisters; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz Journal: HPB (Oxford) Date: 2013-08-29 Impact factor: 3.647
Authors: M M Gaida; F Günther; C Wagner; H Friess; N A Giese; J Schmidt; G M Hänsch; M N Wente Journal: Clin Exp Immunol Date: 2008-09-05 Impact factor: 4.330
Authors: Carmen Guerra; Manuel Collado; Carolina Navas; Alberto J Schuhmacher; Isabel Hernández-Porras; Marta Cañamero; Manuel Rodriguez-Justo; Manuel Serrano; Mariano Barbacid Journal: Cancer Cell Date: 2011-06-14 Impact factor: 31.743
Authors: S Nishihara; S Yazawa; H Iwasaki; M Nakazato; T Kudo; T Ando; H Narimatsu Journal: Biochem Biophys Res Commun Date: 1993-10-29 Impact factor: 3.575
Authors: B A Boone; L Orlichenko; N E Schapiro; P Loughran; G C Gianfrate; J T Ellis; A D Singhi; R Kang; D Tang; M T Lotze; H J Zeh Journal: Cancer Gene Ther Date: 2015-04-24 Impact factor: 5.987
Authors: WonJae Lee; Song Yi Ko; Muhaned S Mohamed; Hilary A Kenny; Ernst Lengyel; Honami Naora Journal: J Exp Med Date: 2018-12-19 Impact factor: 14.307
Authors: Asmita Chopra; Ruben Zamora; Yoram Vodovotz; Jacob C Hodges; Derek Barclay; Randall Brand; Richard L Simmons; Kenneth K Lee; Alessandro Paniccia; Pranav Murthy; Michael T Lotze; Brian A Boone; Amer H Zureikat Journal: J Immunother Date: 2021-06-01 Impact factor: 4.912